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Endoscopic sclerotherapy and banding ligation are
the two preferred methods to treat oesophageal
variceal bleeding. There are many reports dealing
with suchtreatment in cirrhotic patientsbutwe do not
know how good they are to treat varices secondary to
other forms of portal hypertension. Schistosomiais
mansoni is the main cause of portal hypertension and
oesophageal varices in Brazil. We performed a
prospective randomised study to compare: 1) the
efficacy of both treatments in eradicating oesopha-
geal varices, and 2) complications secondary to both
treatments. Forty patients were divided in two
Groups. Both sclerotherapy and banding ligation
were performed until variceal eradication.There were
no severe complications. Variceal eradication was
faster obtained with banding ligation than sclerother-
apy although therewasno statistical difference (mean
number of sessions 3.05 vs 3.72, p=0.053). Benign
complications were equally frequent in both Groups,
although additional sedation was more common in
the sclerotherapy Group. We concluded that both
treatments are equally effective in the eradication of
oesophageal varices, although banding ligation is
better tolerated by the patient and probably faster.
Keywords: Portal hypertension, oesophageal varices, upper
gastrointestinal bleeding, schistosomiasis, endoscopic sclero-
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INTRODUCTION
Upper gastrointestinal haemorrhage (UGH) sec-
ondary to oesophageal varices (EV) rupture is a
severe clinical complication of portal hyperten-
sion (PH) [1]. It occurs in approximately 30% of
patients with hepatic cirrhosis and EV [2, 3].
First episode mortality rate is high, up to 50% of
patients [3, 4]. Re-bleeding in non treated
patients occurs in 47% to 84% of cases and the
correspondent mortality rate ranges from 20% to
70% [5, 61.
Sclerotherapy (ST) and band ligation (BL) are
the two most widely used endoscopic proce-
dures in the treatment of EV [7].
Endoscopic sclerotherapy shows up to 95%
efficacy in the treatment of a severe variceal
bleeding episode [5, 8]. Endoscopic treatment
should be the choice for re-bleeding prophylaxis,
if liver transplantation is not available. ST
should be considered as prophylaxis for the first
variceal bleeding episode in patients with high
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bleeding risk and reasonable life expectancy [4,
7]. However, there is a high incidence of
complications that may reach 70% of procedures
[9].
By eliminating sclerosant solutions, endo-
scopic banding ligation has reduced the compli-
cation rate associated with EV endoscopic
treatment [10-12]. Several prospective studies
have proven the efficacy of such procedure in
the treatment of EV bleeding [13, 14].
Most studies on PH and EV were conducted
in patients with hepatic cirrhosis of several
aetiologies (alcoholic, viral, auto-immune). Stud-
ies in patients with other types of portal
hypertension, such as schistosomiasis, are less
frequently found.
Schistosomiasis mansoni leads to pre-sinusoi-
dal PH and preserved hepatic tissue [15-17],
and is the major cause for PH and variceal
bleeding in Brazil. As a result of a reasonably
sustained liver function, hepatosplenic schisto-
somotic (HSS) patients live longer and better as
compared to cirrhotic, and variceal UGH is their
main clinical manifestation [18]. A number of
studies have proven the efficacy of ST and
surgical procedures (shunts and devasculariza-
tion) in preventing re-bleeding in such patients
[19-21]. The few studies using primary pro-
phylaxis were not conclusive [15, 16]. As far as
we are concerned this is the first study on the
use of BL for oesophageal varices treatment in
HSS patients.
We conducted a randomised prospective
study comparing the efficacy and complications
of ST and BL in the treatment of EV in
schistosomotic patients. Variceal recurrence
was assessed over a six-month period.
MATERIAL AND METHODS
From August 1994 to August 1995, schistosomo-
tic patients over 18 years of age, who had
medium (F2) or large size (F3) oesophageal
varices (according to the Japanese Research
Society for Portal Hypertension criteria [22])
were included in the study. Informed consent
was obtained from all patients and the study
was approved by UNIFESP-Hospital Sao Paulo
Ethics Committee. Aetiology of liver disease was
based on abdominal ultrasound findings, spe-
cific for HSS [23, 24]. Patients with positive
serology for hepatitis B (HBsAg) and C virus
(anti-HCV) as well as those with history of
alcohol intake in the past were excluded.
Patients were randomised into two Groups by
means of sealed envelopes. Group 1 comprised
patients who underwent sclerotherapy treat-
ment and Group 2 those submitted to banding
ligation. There were 20 patients in each Group.
Endoscopic Treatment
Endoscopic procedures were performed by
experienced gastroenterologists, using a Olym-
pus GIF-V10 endoscope. All patients were
sedated with 50 mg of meperidine IV. All
patients, except, 3 were treated electively.
We performed predominantly intra-variceal
injections of 2.5% ethanolamine oleate (Glaxo-
Brasil), through a 7 Fr diameter injection catheter
with a 4mm/23 G needle (Wilson-Cook Medical
Inc., USA). Initial injections were performed
around the cardia. Maximum volume of sclero-
sant was 5 ml/site and 35 ml/session.
Banding ligation was performed according to
usual techniques following the introduction of a
20cm plastic overtube over an oesophageal
dilator (Savary-Gillard), described by Stiegmann
[11], with commercial kits (Bard Inc., USA). The
first O-ring was placed in the distal parts, and
more proximal O-rings also were used in long
varices. The number of O-rings used per session
was not greater than 5.
Follow-up
Sclerotherapy and BL sessions were repeated at
intervals ranging from 10 to 20 days until
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were postponed if large lesions were present.
Patients who had bleeding episodes over the
course of treatment or even after eradication were
hospitalised and underwent urgent endoscopy
for diagnosis of the bleeding site and possible
endoscopic treatment. Patients were referred to
surgery if endoscopy was unsuccessful.
The study was completed six months after
eradication, and at that point another endoscopy
was performed to look for variceal recurrence.
Statistical Analysis
Mann-Whitney test was used to compare means.
All operations were computer analysed (Primer
of Statistics, v 3.02, McGraw-Hill, Inc.,) In all
tests p value was established as 5% or 0.05.
TABLE Feature of the 40 patients previously to the study
Features Group (ES) Group 2 (BL)
N 20 N 20
Sex (M/F) 8/12 10/10
Age
Range 24 70 23 64
Mean 41.95 42.65
Median 39 43
PT (min)* 1.34+ 0.13 1.34 4- 0.16
Albumin (g/dl)* 3.47 4- 0.45 3.81 4- 0.88
AST (u/l)* 15.7 4- 4.4 16.9 4- 5.6
ALT (u/l)* 16.5 4- 6.3 19.1 4- 7.9
"y GT (u/l)* 15.2 4- 4.4 17.6 4- 9.3
Previous surgery 4 2
Sclerotherapy 3 4
Previous UGH 6 6
LV 17 16
RS 14 13
GV 4 3
Gastropathy 4 3
Laboratory figures express the Groups mean+ standard deviation.
LV large size varices; KS red signs; GV gastric varices; Previous
surgery portal hypertension surgery; Gastropathy severe conges-
tive gastropathy at index endoscopy.
RESULTS
Forty patients were enrolled (20 in each Group);
39 returned for the 6 month control examination.
Two patients underwent surgery for uncon-
trolled UGH due to gastric variceal rupture,
prior to EV eradication.
Both Groups were similar regarding sex, age
and laboratory tests (Tab. I). Endoscopic find-
ings and data concerning digestive bleeding and
portal hypertension treatment before the study
showed no significant difference in either Group
(Tab. I).
One patient from Group 1 had ascites at the
time of randomisation. All others had compen-
sated HSS. All patients had peri-portal thickness
(fibrosis) at abdominal ultrasound examination.
All 123 treatment sessions were done in an
elective mode, except for 3 patients (2 in Group 1
and one in Group 2) in whom the first session
was performed as urgent therapy.
Efficacy
In Group 1, before varices were eradicated, two
patients had uncontrolled bleeding from fundic
gastric varices and were referred to surgery. One
died of kidney failure and disseminated intra-
vascular coagulation two days after surgery.
Efficacy of endoscopic treatment was 90%. After
excluding the two operated patients, the number
of sessions required for eradication ranged from
2 to 7 (mean: 3.72). There was no significant
difference when the number of sessions required
to obliterate the varices was compared in both
Groups, however there was a tendency to faster
eradication in Group 2 (p=0.053, Mann-
Whitney test) as shown in Table II. All patients
in Group 2 had their EV eradicated after 1 to 5
sessions (mean 3.05, 100% efficacy). No variceal
bleeding was observed during treatment.
One patient in Group 1 had one UGH episode
due to EV rupture (recurrence) before the end of
treatment, with moderate hemodynamic reper-
cussions. This episode was successfully mana-
ged by endoscopy. The same patient had
another UGH episode four months after EV
eradication. Endoscopic evaluation revealed
congestive gastropathy as the source of bleed-
ing. Beta-blocker treatment was initiated.30 E.S. SIQUEIRA et al.
TABLE II Treatment results for both Groups
Results Group Group 2
(ST) (BL)
N 18" N 20
Sessions before eradication
Total 67 61
Mean** 3.72 3.05
Range 2- 7 5
Sclerosant volume
mean/session 15.4 ml
mean/patient 61.7 ml
Rings
mean/patient 10.7
mean/session 3.6
Eradication rate (%) 90 100
Mortality 1/20 (5%)
values for all items, except mortality, refer to patients in whom
variceal eradication was achieved.
p 0.053 (Mann-Whitney test).
Recurrences
No oesophageal recurrence was found in Group
2. One patient in Group 1 had variceal recur-
rence 6 months after eradication. Varices were
again treated and eradicated with three ST
sessions.
Complications
There was no oesophageal perforation or infec-
tion in either Group. Massive bleeding after
injection occurred in four procedures in Group 1
(5.0%), and all were controlled. Although no
such complication occurred in Group 2, the
difference between both Groups was not statis-
tically significant.
Complaints of dysphagia, odynophagia and
thoracic pain of different intensity and duration
in the days following the procedures were
reported by nearly all patients, with no signifi-
cant difference between the Groups. Nine
patients in Group 1 (45%) required additional
sedation during or at the end Of the procedure
due to intense thoracic pain. Among such
patients, 18/77 (23.38%) procedures needed
additional sedation, all from Group 1.
Overtube placement did not cause any extra
complaint. At the final examination, 3 patients
(15%) from Group 1 and 2 from Group 2 (10%)
showed slight asymptomatic narrowing of the
oesophageal lumen without the necessity of any
therapeutic approach.
Oesophageal membrane injuries (erosions or
ulcerations) were found in all patients. Ulcera-
tions secondary to sclerotherapy were deeper
and more irregular than after BL. Ulcerations
did not cause any episode of bleeding, however
sessions had to be postponed in 11 (14.28%)
procedures in Group 1 and 3 (5.1%) in Group 2
(p =0.147).
Mucosa scars and neo-vascularization were
often noted at the end of treatment. Scars were
more severe in patients in Group 1. Mucosal
bridges were present in two asymptomatic
patients in Group 1. As mentioned above, one
patient in Group 1 developed congestive gastro-
pathy, leading to a digestive bleeding episode.
DISCUSSION
The mortality rate in cirrhosis due to UGH
following EV rupture is high, reaching up to
50% of patients [1, 25]. In Brazil the major cause
of such complication is HSS, and patients have a
better outcome as compared to other aetiologies
[17]. The natural history of HSS is not fully
understand. The estimate number of patients
developing EV is not available nor variceal
bleeding episodes that may occur in the course
of the disease, or the mortality rate in bleeding
episodes. Moreover, studies conducted in this
Group of patients are less frequent than those
concerning cirrhosis, making it impossible to
assert that the results of the treatment for
cirrhosis tally those for schistosomiasis.
Although surgical treatment is largely used in
HSS patients with bleeding EV [15, 21, 26, 27],
endoscopic treatment can also be successfully
used [19, 20, 28]. Data on the role of ST or any
other prophylactic treatment for the first bleed-
ing episode in schistosomotic patients are
limited.ENDOSCOPIC TREATMENT OF OESOPHAGEAL VARICES 31
Our study compared two endoscopic proce-
dures (ST and BL) for EV treatment in schisto-
somotic patients. According to our literature
review, this is the first study to describe the use
of BL in such patients. In the present study, ST
efficacy was confirmed and eradication rate
was 90%.
The average number of ST sessions required
to eradication (3, 72) was similar to the pub-
lished data, both for cirrhosis and.schistosomia-
sis, although only patients with medium and
large size varices were enrolled in this study [13,
14, 19]. No EV bleeding was noted eradication.
Variceal recurrence after sclerotherapy treat-
ment reaches upto 40% in the first year follow-
ing treatment [1, 19, 29]. Our recurrence rate
after 6 months was 5%.
Incidence of post ST complications was also
similar to those reported in the literature [14, 19].
There were no episodes of severe complications
such as oesophageal perforation, infection and
oesophageal symptomatic stricture. Bleeding
episodes triggered during the procedures oc-
curred in 5.1% of the cases. Despite the presence
of mucosal lesions (erosions and ulcerations) in
all patients, symptoms reported by the patients
during follow-up (dysphagia, odynophagia and
thoracic pain) cannot be imputed to them,
because at the time of the assessment they were
already asymptomatic and lesions were still
present. Such complaints were self-limited, and
required no medication. In 3.1% of the proce-
dures, the use of additional sedation was
necessary, this figure is higher than reported in
the literature.
In the present study, BL showed efficacy of
100%. The average number of sessions required
to eradicate the varices was 3.05, smaller than
patients submitted to ST (3.72; p 0.053). Should
there be an increase in the sample size, sig-
nificance would probably be obtained. Besides,
in the present study a maximum of five O-rings/
session was established, and using more O-
rings/session could lead to a reduction in the
number of sessions. That approach does not
increase complications, as observed in other
patients treated in our Unit and not enrolled in
the study.
In this Group, acute mucosal lesions (erosions
and ulcerations) were also described in all
patients. Although asymptomatic such lesions
accounted for some of the postponement of new
sessions in both Groups. All lesions healed
spontaneously.
Mucosal scars were also described in most
patients. Both acute (erosions and ulcerations)
and chronic (scars, neo-vascularization) lesions
were less severe in the BL Group.
Occurrence of only one episode of digestive
bleeding due to congestive gastropathy in the ST
Group does not entitle us to state that such
complication occurs more often in this Group.
Incidence of variceal recurrence following BL
is yet to be defined. Some authors claim it to
occur more often in cirrhotic patients when
compared to ST [30]. No cases of EV recurrence
had been noticed in our study, up to six months
following variceal eradication, patients from
both Groups are still being followed up for
detection of late recurrences.
At the end of the study, the efficacy and safety
of BL as EV treatment in HSS patients were
confirmed. When compared to ST, BL was less
painful and maybe faster in EV eradication.
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